AzTrials
AzTrials

Epidural AnesthesiaNCT03721432

The Effect of Oral Pregabalin on Epidural-induced Shivering and Epidural Characteristics

A study testing Pregabalin 150mg in people with Epidural Anesthesia and Shivering, run by Beni-Suef University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background: The previous reports tried to reduce shivering and improve neuroaxial anesthesia characteristics by the systemic use of different drugs. This study was directed to evaluate the effect of pregabalin premedication on both shivering and epidural outcome data following single shot loading. Read more about this study

Who is it for?
Ages 20 to 60 years, women only
Conditions the study is for
Epidural Anesthesia, Shivering
What is being tested?
Pregabalin 150mg
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
77 participants
Where
1 siteEgypt
Study dates
20 May 2018to 15 Nov 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 60 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • adults female patients (20 - 60 years old)
  • with an American society of Anesthegiologists physical status (ASA) I-II
  • undergoing gynecological surgery

Who cannot join

  • ASA class was more than II,
  • anticipated difficult epidural insertion
  • any contraindication to epidural anesthesia, if any patient developed wet or bloody tab, or the patients were under psychotropic or antiepileptic therapy.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Beni suef university hospiital

    Banī Suwayf, 62511

Other trials in Egypt

About this study

Official title: The Effect of Oral Pregabalin on Epidural-induced Shivering and Epidural Characteristics in Gynecological Surgeries, a Prospective Randomized Double-blind Study

  • Background: The previous reports tried to reduce shivering and improve neuroaxial anesthesia characteristics by the systemic use of different drugs. This study was directed to evaluate the effect of pregabalin premedication on both shivering and epidural outcome data following single shot loading.
  • Patients and Methods: Eighty patients, ASA grade I and II, undergoing surgeries under epidural anesthesia were studied. The patients were divided into two groups: Pregabalin group and Control group in which the patients received 150 mg of pregabalin and placebo capsules respectively sixty minutes prior to surgery. Following epidural loading, the onset and degree of shivering were compared between the two groups. Also, the epidural outcome including onset, level and duration were traced and compared. The perioperative hemodynamics, sedation scores, patient satisfaction and side effects were followed up and registered.
Read the detailed description

After obtaining the ethical committee approval of Beni Suef University hospital, in Egypt and an informed consent from the patients, Eighty female patients with an American society of Anesthegiologists physical status (ASA) I-II who were undergoing gynecological surgery (Posterior repair and transobturator transfixation) under epidural anesthesia, were enrolled in this randomized double -blind study in May 2018.

The patients were excluded from the study if ASA class was more than II, anticipated difficult epidural insertion or there was any contraindication to epidural anesthesia, if any patient developed wet or bloody tab, or the patients were under psychotropic or antiepileptic therapy.

The 80 Patients were randomly allocated into one of two groups (using sealed opaque numbered envelopes indicating the group of each patient, carried out by an independent anesthesiologist and given to the ward nurse) [40 patients in each group]:

  • Pregabalin group (P), [n=40]: received pregabalin 150 mg capsules (Lyrica®,Pfizer) sixty minutes prior to the epidural insertion.
  • Control group (C), [n=40]: received placebo capsules sixty minutes prior to epidural insertion.

Prior to administration of study drugs, mean arterial blood pressure (MAP), heart rate (HR), oxygen saturation (SpO2), and tympanic temperature (T temp) were taken as [baseline reading]. Upon reaching the operation theater, a second set of readings were taken [preoperative reading], together with sedation score using a 4 points "Modified Wilson" Sedation Scale [1=awake; 2=drowsy but arousable to command; 3= asleep but arousable to mild physical stimulation; and 4= asleep but not arousable to mild physical stimulation].

On the operating table and after attaching the standard monitoring [5 lead ECG, pulse oximetry, non-invasive arterial blood pressure], the epidural anesthesia was standardized for all patients. After intravenous infusion of 500 ml of lactated Ringer's solution in a wide-bore canula, the epidural catheter was inserted in a lateral position. Following the exclusion of both subarachnoid and intravascular insertion of the catheter, a loading epidural dose of 10 ml levo-bupivacaine 0.5% and 50 mcg fentanyl were injected.

The hemodynamic readings [MAP, HR and SpO2] were monitored and registered every 5 minutes (as routine practice) and tympanic temperature [T temp] was taken upon arrival to operating room, after activation of epidural, then every 15 minutes till the end of surgery.

Intraoperatively, arterial blood pressure was maintained within 20 % of the baseline readings using intravenous boluses of Lactated Ringer's solution and 6 mg increments of ephedrine (if required). Bradycardia (HR less than 60 beats per minutes) was treated with intravenous atropine boluses 0.6 mg.

Also, all patients were active warmed using a convection machine (hot air blower).

Shivering (as a primary outcome) was graded by a blinded observer during the intraoperative and postoperative period using the scale validated by Crossley and Mahajan and Tsai and Chu: [0= no shivering, 1= piloerection or peripheral vasoconstriction but no visible shivering, 2= muscular activity in only one muscle group, 3= muscular activity in more than one muscle group but not generalized shivering, 4= shivering involving the whole body]. Grades 3, and 4 shivering for at least 3 minutes were considered positive, and maximum shivering was considered if generalized shivering interfering with ECG monitoring. Positive shivering or lower grade shivering but described as distressful by the patient were treated with intravenous administration of meperidine 20 mg. If no improvement after this management, the patient was excluded from the study.

For the selection of safe and effective anti-shivering treatment, the medications were revised and meperidine in this small dose was picked up due to its effectiveness in treatment and the epidural parameters will not be significantly affected when compared to ketanserine, doxapram, clonidine, magnesium, ketamine, orphenadrine, methylphenidate, pentazocin and nefopam.

At the end of surgery, the patients were transferred to PACU (for one hour), where hemodynamics and tympanic temperature were taking (every 15 minutes). Shivering was also observed and scaled and treated the same way as intraoperatively. Patients were only discharged from PACU if modified Aldrete score was ≥ 9 after registering and treating any other complications.

Postoperatively, when the patients started to experience pain at the surgical site and according to the acute pain management protocol by the anesthesia department in the hospital, a loading of levo-bupivacaine 0.125% 8 ml was given followed by infusion of levo-bupivacaine 0.125% and fentanyl 2mcg/ ml at a rate of 6 ml/hour.

Any perioperative complications (e.g. bradycardia, hypotension, desaturation or nausea and vomiting) were observed, registered and treated appropriately.

The following were observed (by anaesthetist blinded to the studied drugs):

  • Demographic data (age, weight and height), duration of surgery (in minutes).
  • Tympanic temperature (T temp.) in Celsius degree as baseline (before drug intake), preoperative (on arrival to operating room), after epidural loading, then every 15 minutes intraoperative.
  • Shivering (as a primary outcome): incidence of positive shivering (at any time), incidence of maximum shivering (at any time) and median and range of shivering severity between the two studied groups.
  • Sedation: assessed 60 minutes after studied drug in take (preoperatively).
  • Epidural characteristics (as secondary outcome): onset of the block (the time from epidural loading until feeling of numbness in the lower extremities), duration of the block (the time from the onset till starting feeling of pain at the surgical site) and level of the block (assessed by the ice technique).
  • Meperidine consumption: total consumed dose of meperidine in both groups.
Being tested
Pregabalin 150mg, Placebo oral capsule

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Pregabalin 150mgDrug

    Also called Lyrica

    pregabalin 150 mg capsules (Lyrica®,Pfizer) given 60 minutes prior to epidural anesthesia

  • Placebo oral capsuleDrug

    Placebo oral capsule given 60 minutes prior to epidural anesthesia

Study groups in NCT03721432
Study groupRoleWhat they receive
Pregabalin group (P)Experimentalreceived pregabalin 150 mg capsules (Lyrica®,Pfizer) sixty minutes prior to the epidural insertion.
Receives: Drug: Pregabalin 150mg
Control group (C)Placebo comparatorreceived placebo capsules sixty minutes prior to epidural insertion.
Receives: Drug: Placebo oral capsule

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. - Shivering

    incidence of positive shivering ,

    Measured: starting from epiural injection, up to 60 minutes after epidural anesthesia

  2. Shivering

    incidence of maximum shivering

    Measured: starting from epiural injection, up to 60 minutes after epidural anesthesia

Secondary outcomes (2)
  1. - Epidural characteristics

    onset of the block (the time from epidural loading until feeling of numbness in the lower extremities)

    Measured: from epidural injection till numbing sensation (approximately 10 minutes)

  2. Epidural characteristics

    duration of the block (the time from the onset till starting feeling of pain at the surgical site)

    Measured: from epidural onset to starting feeling pain (approximately 90 minutes)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Oct 2018
  2. Study start20 May 2018
  3. Primary completion15 Nov 2018
  4. Study completion15 Nov 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
77 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03721432
Sponsor's protocol ID
FM-BSU REC 006/2018
Status last verified
Jan 2019
First submitted
10 Oct 2018
Last updated
23 Jan 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: participant data are confidential and can only be exposed uopn legal reasons

Questions about this trial

What is this clinical trial studying?

A study testing Pregabalin 150mg in people with Epidural Anesthesia and Shivering, run by Beni-Suef University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Jan 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

- Shivering (time frame: starting from epiural injection, up to 60 minutes after epidural anesthesia). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jan 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in